Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease

被引:50
作者
Aharoni, Rina [1 ]
Kayhan, Basak
Brenner, Ori
Domev, Hagit
Labunskay, Galya
Arnon, Ruth
机构
[1] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel
关键词
D O I
10.1124/jpet.106.103192
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) is characterized by detrimental immune reactivity in the gut and imbalance between proinflammatory and anti-inflammatory reactivity. In an attempt to down-regulate colitis, we investigated the effect of the immunomodulator glatiramer acetate (GA, Copaxone, copolymer 1) on two murine models of IBD, chemically induced and spontaneous. Acute experimental colitis of different levels of severity was induced in C57BL/6 mice by dextran sulfate sodium (DSS) administered orally at different concentrations and frequencies. It was manifested in weight loss, intestinal bleeding, and diarrhea, as well as by macroscopic and microscopic colon damage. GA treatment led to amelioration of all of these pathological manifestations, resulting in improved long-term survival. Moreover, even when colitis was induced by three cycles of DSS in this highly susceptible mouse strain, as well as in BALB/c mice that exhibit a chronic disease pattern, a substantial reduction in disease activity and mortality was obtained. GA treatment induced a beneficial effect also in a spontaneous model of colitis developed in the C3H/HeJBir IL-10-deficient mice. The detrimental proinflammatory response manifested by proliferation, tumor necrosis factor-alpha, and interferon-gamma expression was modulated by GA, whereas the regulatory anti-inflammatory transforming growth factor-beta and IL-10 cytokines response was elevated. This was demonstrated on the level of protein secretion in splenocytes and local mesenteric lymphocytes in response to syngeneic colon extract and in the overall response to anti-CD3, as well as on the level of mRNA expression in the colon.
引用
收藏
页码:68 / 78
页数:11
相关论文
共 30 条
[1]   Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis [J].
Aharoni, R ;
Kayhan, B ;
Arnon, R .
INFLAMMATORY BOWEL DISEASES, 2005, 11 (02) :106-115
[2]   Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [J].
Aharoni, R ;
Kayhan, B ;
Eilam, R ;
Sela, M ;
Arnon, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14157-14162
[3]   Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 [J].
Aharoni, R ;
Teitelbaum, D ;
Sela, M ;
Arnon, R .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 91 (1-2) :135-146
[4]   Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis [J].
Aharoni, R ;
Teitelbaum, D ;
Sela, M ;
Arnon, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10821-10826
[5]   Copolymer 1 inhibits manifestations of graft rejection [J].
Aharoni, R ;
Teitelbaum, D ;
Arnon, R ;
Sela, M .
TRANSPLANTATION, 2001, 72 (04) :598-605
[6]   Immunomodulation by the copolymer glatiramer acetate [J].
Arnon, R ;
Sela, M .
JOURNAL OF MOLECULAR RECOGNITION, 2003, 16 (06) :412-421
[7]   Management of ulcerative colitis and Crohn's disease [J].
Baert, F ;
Vermeire, S ;
Noman, M ;
Van Assche, G ;
Haens, GD ;
Rutgeerts, P .
ACTA CLINICA BELGICA, 2004, 59 (05) :304-314
[8]   Insights from mouse models of colitis [J].
Boismenu, R ;
Chen, YP .
JOURNAL OF LEUKOCYTE BIOLOGY, 2000, 67 (03) :267-278
[9]   TGF-β1 production in inflammatory bowel disease:: differing production patterns in Crohn's disease and ulcerative colitis [J].
Del Zotto, B ;
Mumolo, G ;
Pronio, AM ;
Montesani, C ;
Tersigni, R ;
Boirivant, M .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 134 (01) :120-126
[10]  
Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385